Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio dell'agonista orale TLR8 Selgantolimod su HBsAg in partecipanti con epatite cronica B e HIV

Sicurezza, tollerabilità e impatto dell'agonista orale TLR8 Selgantolimod sull'HBsAg nei partecipanti con epatite cronica B e HIV

The study aimed to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both chronic hepatitis B (CHB) and HIV who had received suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study also evaluated if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.

The primary hypotheses of this study were:

  1. Administration of the oral TLR8 agonist SLGN will be safe and well-tolerated in participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
  2. TLR8 stimulation with SLGN will reduce HBsAg titers in the blood of participants with both CHB and HIV on suppressive antiviral therapy for both viruses.

Panoramica dello studio

Stato

Terminato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

A5394 was a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with SLGN. Participants were randomized in a 3:1 ratio to receive SLGN or its placebo, and randomization was stratified by HBeAg status. Participants were planned to be on study for up to 48 weeks (24-week treatment phase and 24-week post-treatment follow-up). All participants were required to remain on their non-study-provided antiviral therapy throughout the study.

The primary efficacy analysis was planned to be conducted as a single-arm study of the SLGN study arm.

Accrual was terminated early and did not reach the target sample size of 48 due to ACTG Network funding disruptions.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

29

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Rio de Janeiro, Brasile, 21040-360
        • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasile, 91350-180
        • Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site ID: 12201)
      • Lima, Perù, 04
        • Barranco CRS (Site ID: 11301)
    • California
      • San Diego, California, Stati Uniti, 92103
        • UCSD Antiviral Research Center CRS (Site ID: 701)
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30308
        • The Ponce de Leon Center CRS (Site ID: 5802)
    • New York
      • New York, New York, Stati Uniti, 10011
        • Weill Cornell Chelsea CRS (Site ID: 7804)
    • North Carolina
      • Greensboro, North Carolina, Stati Uniti, 27401
        • Greensboro CRS (Site ID: 3203)
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45267-0405
        • Cincinnati Clinical Research Site (Site ID: 2401)
      • Cleveland, Ohio, Stati Uniti, 44106
        • Case CRS (Site ID: 2501)
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15213
        • Univ of Pittsburgh (Site ID: 1001)
      • Chiang Mai, Tailandia, 50200
        • Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784)
    • Bangkok
      • Pathum Wan, Bangkok, Tailandia, 10330
        • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. HIV-1 infection
  2. Effective antiviral therapy for HIV (ART) and HBV that includes TDF, TAF, TDF/FTC, TDF/3TC (tenofovir disoproxil fumarate plus lamivudine), TAF/FTC, or entecavir (ETV), for ≥5 years immediately prior to study entry. ART is defined as including a minimum of two anti-HIV antivirals.
  3. CD4+ cell count ≥350 cells/mm3
  4. HIV-1 RNA <50 copies/mL measured on at least two occasions at least 12 weeks apart, with no documented value >200 copies/mL, over the 12 months prior to study entry.
  5. Positive or negative HBeAg
  6. Negative anti-HDV
  7. Current CHB infection
  8. HBV DNA level <50 IU/mL measured on at least two occasions at least 12 weeks apart, with no documented value ≥50 IU/mL, over the 12 months prior to study entry.
  9. Quantitative HBsAg >1000 IU/mL
  10. Hepatitis C virus (HCV) antibody negative, or if the participant is HCV antibody positive, an undetectable HCV RNA.
  11. Participants must agree to stay on an effective antiviral therapy for HIV (ART) and HBV throughout the study.

Exclusion Criteria:

  1. Receipt of treatment for HCV within 24 weeks prior to study entry
  2. Evidence of advanced fibrosis or cirrhosis (Metavir ≥F3 or equivalent).
  3. Current or prior history of clinical hepatic decompensation (e.g., ascites, encephalopathy, or variceal hemorrhage)
  4. History of HCC or cholangiocarcinoma
  5. Malignancy within 5 years prior to study entry. NOTE: A history of non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell skin cancer) is not exclusionary.
  6. History of solid organ transplantation
  7. Presence of any active or acute AIDS-defining opportunistic infections within 60 days prior to study entry
  8. History of uveitis or posterior synechiae
  9. Breastfeeding

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm A

Participants received Selgantolimod 3 mg (two 1.5 mg tablets) once weekly for 24 weeks.

Two 1.5 mg tablets taken orally once a week

Altri nomi:
  • SLGN
Comparatore placebo: Arm B

Participants received matching Placebo for Selgantolimod once weekly for 24 weeks.

Two matching placebo tablets taken orally once a week

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A
Lasso di tempo: From study treatment initiation through Week 24

An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition. All AEs that are reported must have their severity graded.

Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017. Adverse events were graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Higher scores/grades mean a worse outcome.

The proportion of participants with Grade 2 or higher adverse events was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From study treatment initiation through Week 24
Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A
Lasso di tempo: From study treatment initiation through Week 24

The proportion of participants who had premature discontinuation of Selgantolimod due to adverse event(s) was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From study treatment initiation through Week 24
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24
Lasso di tempo: Week 24

The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Week 24

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in qHBsAg at Any Time During the Study After SLGN Treatment Initiation
Lasso di tempo: From Baseline (Entry) through Week 48

The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24
Lasso di tempo: Week 24

The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

Week 24
Proportion of Participants With ≥0.5 log10 IU/mL Decline in qHBsAg From Baseline at Any Time During the Study After SLGN Treatment Initiation
Lasso di tempo: From Baseline (Entry) through Week 48

The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Proportion of Participants Who Achieve HBsAg Loss After SLGN Initiation and Who Sustain HBsAg Loss During Follow-up
Lasso di tempo: From Baseline (Entry) through Week 48

Sustained HBsAg loss is defined as HBsAg converting from positive to negative after initiation of SLGN, without any subsequent positive HBsAg result. The proportion of participants who achieved HBsAg loss after SLGN initiation and who sustained HBsAg loss during follow-up will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Changes From Baseline in qHBsAg Levels
Lasso di tempo: Baseline (Entry) and Weeks 4, 12, 24, 36 and 48

The absolute change in qHBsAg level refers to the value at the follow-up time point minus the value at Baseline (Entry).

Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
Proportion of Hepatitis B E-antigen (HBeAg) Positive Participants at Baseline Who Lose HBeAg at Any Time During the Study
Lasso di tempo: From Baseline (Entry) through Week 48

HBeAg loss is defined as HBeAg changing from positive to negative. The proportion of participants who lose HBeAg at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Proportion of Hepatitis B E-antibody (Anti-HBe) Negative Participants at Baseline Who Develop Anti-HBe at Any Time During the Study
Lasso di tempo: From Baseline (Entry) through Week 48

Developing anti-HBe, or anti-HBe gain, is defined as HBeAb changing from negative to positive. The proportion of participants who develop HBeAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Proportion of Hepatitis B Surface Antibody (Anti-HBs) Negative Participants at Baseline Who Develop Anti-HBs at Any Time During the Study
Lasso di tempo: From Baseline (Entry) through Week 48

Developing anti-HBs, or anti-HBs gain, is defined as HBsAb changing from negative to positive. The proportion of participants who develop HBsAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data.

From Baseline (Entry) through Week 48
Number of Participants With Plasma HIV RNA >50 Copies/mL
Lasso di tempo: Weeks 2, 4, 24 and 48

The number of participants with detectable plasma HIV RNA >50 copies/mL will be reported.

Weeks 2, 4, 24 and 48
Number of Participants With Serum HBV DNA >50 IU/mL
Lasso di tempo: Weeks 2, 4, 24 and 48

The number of participants with detectable serum HBV DNA >50 copies/mL will be reported.

Weeks 2, 4, 24 and 48

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 maggio 2023

Completamento primario (Effettivo)

29 ottobre 2025

Completamento dello studio (Effettivo)

8 aprile 2026

Date di iscrizione allo studio

Primo inviato

9 settembre 2022

Primo inviato che soddisfa i criteri di controllo qualità

20 settembre 2022

Primo Inserito (Effettivo)

22 settembre 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

26 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • A5394

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Individual participant data that underlie results in the publication, after deidentification

Periodo di condivisione IPD

Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH

Criteri di accesso alla condivisione IPD

With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.

For what types of analyses? To achieve aims in the proposal approved by the ACTG.

By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .